All patients (N = 20,462) N (%) | Breast Cancer Death (N = 842) | CVD Death (N = 696) | |
---|---|---|---|
Age (years) | |||
21–34 | 302 (1.5%) | 13 (1.5%) | 3 (0.4%) |
35–39 | 571 (2.8%) | 36 (4.3%) | 8 (1.2%) |
40–44 | 1340 (6.6%) | 65 (7.7%) | 12 (1.7%) |
45–49 | 2167 (10.6%) | 81 (9.6%) | 21 (3.0%) |
50–54 | 2604 (12.7%) | 90 (10.7%) | 33 (4.7%) |
55–59 | 2962 (14.5%) | 104 (12.4%) | 39 (5.6%) |
60–64 | 2866 (14.0%) | 106 (12.6%) | 52 (7.5%) |
65–69 | 2482 (12.1%) | 78 (9.3%) | 71 (10.2%) |
70–74 | 2004 (9.8%) | 81 (9.6%) | 109 (15.7%) |
75 + | 3164 (15.5%) | 188 (22.3%) | 348 (50.0%) |
Race | |||
Non-Hispanic White | 14,181 (69.3%) | 601 (71.4%) | 531 (76.3%) |
Hispanic White | 1985 (9.7%) | 77 (9.1%) | 38 (5.5%) |
Non-Hispanic Black | 1500 (7.3%) | 81(9.6%) | 85 (12.2%) |
Hispanic Black | 7 (< 0.1%) | 0 | 0 |
Asian/Pacific Islander | 2719 (13.3%) | 80 (9.5%) | 40 (5.8%) |
Other/Unknown | 70 (0.3%) | 3 (0.4%) | 2 (0.2%) |
Smoking status at diagnosis | |||
Current smoker | 2430 (11.9%) | 109 (13.0%) | 126 (18.1%) |
Former smoker | 3095 (24.0%) | 100 (11.9%) | 97 (13.9%) |
Non-smoker | 7389 (36.1%) | 162 (19.2%) | 97 (13.9%) |
Unknown | 7548 (36.9%) | 471 (55.9%) | 376 (54.0%) |
Diabetes | 2669 (13.1%) | 104 (12.4%) | 160 (23.0%) |
Charlson comorbidity | |||
0 | 13,130 (64.2%) | 544 (64.6%) | 277 (39.8%) |
1–2 | 6137 (30.0%) | 240 (28.5%) | 288 (41.4%) |
3 + | 1163 (5.7%) | 56 (6.7%) | 130 (18.7%) |
unknown | 32 (0.2%) | 2 (0.2%) | 1 (0.1%) |
Breast Cancer Characteristics | |||
Bilateral Unilateral—Right Unilateral-Left Unilateral—Unknown | 138 (0.7%) 9842 (48.1%) 10,476 (51.2%) 6 (< .01%) | 4 (0.5%) | 8 (1.2%) |
Surgery | |||
None | 560 (2.7%) | 59 (7.0%) | 39 (5.6%) |
Lumpectomy | 11,583 (56.6%) | 270 (32.1%) | 321 (46.1%) |
Mastectomy | 8309 (40.6%) | 512 (60.8%) | 334 (48.0%) |
Unknown | 10 (0.1%) | 1 (0.1%) | 2 (0.3%) |
Grade | |||
1 Well differentiated | 4734 (23.1%) | 37 (4.4%) | 130 (18.7%) |
2 Moderately differentiated | 8336 (40.7%) | 287 (34.1%) | 272 (39.1%) |
3 Poorly differentiated | 5481(26.8%) | 424 (50.4%) | 198 (28.5%) |
4 Diffuse | 259 (1.3%) | 20 (2.4%) | 7 (1.0%) |
Unknown | 1652 (8.1%) | 74 (8.8%) | 89 (12.8%) |
Stage | |||
1 | 10,843 (53.0%) | 127 (15.1%) | 294 (42.3%) |
2 | 7806 (38.2%) | 444 (52.7%) | 316 (45.4%) |
3 | 1813 (8.9%) | 271 (32.2%) | 86 (12.4%) |
Tumor size | |||
≤ 2 cm | 13,727 (67.1%) | 269 (32.0%) | 393 (56.5%) |
(2,5] cm | 5723 (28.0%) | 411 (48.8%) | 244 (35.1%) |
> 5 cm | 838 (4.1%) | 117 (13.9%) | 44 (6.3%) |
Diffuse or Unknown | 174 (0.9%) | 45 (5.3%) | 15 (2.2%) |
ER/PR | |||
Positive | 11,917 (58.2%) | 393 (46.7%) | 442 (63.5%) |
Negative | 2689 (13.1%) | 253 (30.1%) | 105 (15.1%) |
Unknown/not done | 5856 (28.6%) | 196 (23.3%) | 149 (21.4%) |
HER2 | |||
Positive | 1862 (9.1%) | 110 (13.1%) | 49 (7.0%) |
Negative | 11,938 (58.3%) | 422 (50.1%) | 417 (59.9%) |
Unknown/not done | 6662 (32.6%) | 310 (36.8%) | 230 (33.1%) |
Positive Lymph Nodes | |||
0 | 14,150 (69.2%) | 327 (71.1%) | 449 (64.5%) |
1–3 | 4429 (21.7%) | 234 (21.3%) | 156 (22.4%) |
> 3 | 1851 (9.1%) | 279 (7.5%) | 87 (12.5%) |
None examined/unknown | 32 (0.2%) | 2 (0.1%) | 4 (0.6%) |
Treatments received | |||
Any chemotherapy | 9639 (47.1%) | 596 (70.8%) | 204 (29.3%) |
Taxanes | 2806 (13.7%) | 220 (26.1%) | 47 (6.8%) |
Targeted Therapy | 1206 (5.9%) | 78 (9.3%) | 16 (2.3%) |
Alkylating Agents | 1626 (8.0%) | 113 (13.4%) | 41 (5.9%) |
Antimetabolites | 1061 (5.2%) | 174 (20.7%) | 33 (4.7%) |
Vinca Alkaloids | 364 (1.8%) | 94 (11.2%) | 14 (2.0%) |
Other | 1174 (5.7%) | 133 (15.8%) | 23 (3.3%) |
No Chemotherapy | 10,823 (52.9%) | 246 (29.2%) | 492 (70.7%) |
Any hormonal therapy | 8463 (41.4%) | 265 (31.5%) | 282 (40.5%) |
Any radiation | 6621(32.4%) | 247(29.3%) | 184 (26.4%) |